Regenxbio Inc
Regenxbio Inc (RGNX) is a clinical‑stage biotechnology company focused on developing gene therapies using its proprietary NAV AAV platform. Investors should know it centres on designing and delivering adeno‑associated virus (AAV) vectors to address a range of inherited and acquired conditions, and it supports programmes through partnerships and licensing. With a market capitalisation of approximately $661.23M, Regenxbio can offer upside tied to positive clinical readouts or successful collaborations, but it remains subject to the typical biotech risks: long development timelines, high R&D spend, binary trial results and regulatory uncertainty. The share price can be volatile and funding or dilution remains possible. This overview is general educational information and not personalised investment advice; Regenxbio may be suitable only for investors who understand and accept the high-risk, high-uncertainty nature of clinical-stage biotech investments.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Regenxbio's stock with a target price of $31.46, indicating significant growth potential.
Financial Health
Regenxbio Inc is earning strong revenue and cash flow, with a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring RGNX
Gene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: July 25, 2025
Explore BasketWhy You’ll Want to Watch This Stock
NAV AAV Platform
A proprietary AAV platform underpins many programmes and collaborations — it may enable broad applications, though development is costly and outcomes uncertain.
Clinical Milestones
Trial readouts and regulatory steps tend to drive share movements; positive data can increase value, while setbacks are common and may be swift.
Partnerships Matter
Collaborations can provide funding and expertise and help de‑risk programmes, but commercial returns depend on successful development and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
